Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

被引：0

作者：

Ide H. ^{[1
]}

Kikuchi E. ^{[1
]}

Mikami S. ^{[1
]}

Miyajima A. ^{[1
]}

Oya M. ^{[1
]}

机构：

[1] Department of Urology and Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo

来源：

BMC Research Notes | / 7卷 / 1期

关键词：

5-fluorouracil; Dihydropyrimidine dehydrogenase; S-1; Thymidylate synthase; Urothelial carcinoma;

D O I：

10.1186/1756-0500-7-646

中图分类号：

学科分类号：

摘要：

Background: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that regulates the metabolism of 5-FU and prognosis in bladder cancer. Furthermore, to our knowledge, there has also been no such report in T1G3 bladder tumors treated with BCG. Therefore, we evaluated enzymes that regulate the metabolism of 5-FU in T1G3 tumors treated with BCG immunotherapy using the Danenberg tumor profile (DTP) method, a highly accurate measurement of RNA from paraffin-embedded specimens. Methods. This study included 28 patients with T1G3 bladder cancer, each of whom underwent complete transurethral tumor resection and BCG intravesical instillation at our institution. The median follow-up period was 39 months (range, 3 to 159 months). The DTP method was used to analyze the mRNA expression of 3 enzymes related to 5-FU: DPD, orotate phosphoribosyltransferase (OPRT), and thymidylate synthase (TS). Results: Among the 28 patients, 13 developed recurrences (46.4%) and 5 experienced disease progression (17.9%). An elevated DPD mRNA level was significantly associated with recurrence (p = 0.048) and progression (p = 0.045). However, TS and OPRT mRNA levels were not significantly associated with any other clinical features or outcomes. Furthermore, the high DPD group had a significantly lower recurrence-free survival rate than the low DPD group (p = 0.047). Among patients with low DPD, the 2- and 5-year recurrence-free survival rates were 88.9% and 74.1%, respectively; while among patients with high DPD, the corresponding rates were 61.3% and 36.8%, respectively. TS and OPRT were not significantly associated with recurrence-free survival rates. Conclusion: DPD is significantly associated with recurrence and progression among T1G3 bladder cancer patients treated with BCG. © 2014Ide et al.; licensee BioMed Central Ltd.

引用

共 29 条

[21] External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guerin [J].

Kohjimoto, Yasuo ;

Kusumoto, Hiroki ;

Nishizawa, Satoshi ;

Kikkawa, Kazuro ;

Kodama, Yoshiki ;

Ko, Motohiro ;

Matsumura, Nagahide ;

Hara, Isao .

INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (12) :1201-1207

[22] Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer [J].

Vartolomei, Mihai Dorin ;

Ferro, Matteo ;

Cantiello, Francesco ;

Lucarelli, Giuseppe ;

Di Stasi, Savino ;

Hurle, Rodolfo ;

Guazzoni, Gioyo ;

Busetto, Gian Maria ;

De Berardinis, Ettore ;

Damiano, Rocco ;

Perdona, Sisto ;

Verze, Paolo ;

La Rocca, Roberto ;

Borghesi, Marco ;

Schiavina, Riccardo ;

Brunocilla, Eugenio ;

Almeida, Gilberto L. ;

Bove, Pierluigi ;

Lima, Estevao ;

Grimaldi, Giovanni ;

Autorino, Riccardo ;

Crisan, Nicolae ;

Abu Farhan, Abdal Rahman ;

Battaglia, Michele ;

Serretta, Vincenzo ;

Russo, Giorgio Ivan ;

Morgia, Giuseppe ;

Terracciano, Daniela ;

Musi, Gennaro ;

de Cobelli, Ottavio ;

Mirone, Vincenzo ;

Shariat, Shahrokh F. .

CLINICAL GENITOURINARY CANCER, 2018, 16 (06) :445-452

[23] A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study [J].

Hahn, Noah M. ;

O'Donnell, Michael A. ;

Efstathiou, Jason A. ;

Zahurak, Marianna ;

Rosner, Gary L. ;

Smith, Jeff ;

Kates, Max R. ;

Bivalacqua, Trinity J. ;

Tran, Phuoc T. ;

Song, Daniel Y. ;

Baras, Alex S. ;

Matoso, Andres ;

Choi, Woonyoung ;

Smitha, Kellie N. ;

Pardoll, Drew M. ;

Marchionni, Luigi ;

McGuire, Bridget ;

Phelan, Mary Grace ;

Johnson, Burles A. ;

O'Neal, Tanya ;

McConkey, David J. ;

Roseo, Tracy L. ;

Bjurlin, Marc ;

Lim, Emerson A. ;

Drake, Charles G. ;

McKiernan, James M. ;

Deutschr, Israel ;

Andersonr, Christopher B. ;

Lamm, Donald L. ;

Geynisman, Daniel M. ;

Plimack, Elizabeth R. ;

Hallmany, Mark A. ;

Horwitzy, Eric M. ;

Al-Saleem, Essel ;

Chen, David Y. T. ;

Greenberg, Richard E. ;

Kutikov, Alexander ;

Guo, Gordon ;

Masterson, Timothy A. ;

Adra, Nabil ;

Kaimakliotis, Hristos Z. .

EUROPEAN UROLOGY, 2023, 83 (06) :486-494

[24] Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC) [J].

Delcourt, Clara ;

Gemival, Pierre ;

Nouhaud, Francois Xavier ;

Gobet, Francoise ;

Gillibert, Andre ;

Ferlicot, Sophie ;

Sabourin, Jean Christophe ;

Irani, Jacques ;

Pfister, Christian .

WORLD JOURNAL OF UROLOGY, 2020, 38 (06) :1517-1524

[25] Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guerin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-Muscle-invasive Bladder Cancer in Intermediate-and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial [J].

Solsona, Eduardo ;

Madero, Rosario ;

Chantada, Venancio ;

Fernandez, Jesus M. ;

Zabala, Juan A. ;

Portillo, Jose A. ;

Alonso, Jose M. ;

Astobieta, Ander ;

Unda, Miguel ;

Martinez-Pineiro, Luis ;

Rabadan, Mariano ;

Ojea, Antonio ;

Rodriguez-Molina, Jesus ;

Beardo, Pastora ;

Muntanola, Pedro ;

Gomez, Matias ;

Montesinos, Manuel ;

Pineiro, Jose A. Martinez .

EUROPEAN UROLOGY, 2015, 67 (03) :508-516

[26] Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Gu,rin Therapy [J].

Fukumoto, Keishiro ;

Kikuchi, Eiji ;

Mikami, Shuji ;

Hayakawa, Nozomi ;

Matsumoto, Kazuhiro ;

Niwa, Naoya ;

Oya, Mototsugu .

ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (08) :2484-2491

[27] Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC) [J].

Shindo, Tetsuya ;

Masumori, Naoya ;

Kitamura, Hiroshi ;

Tanaka, Toshiaki ;

Fukuta, Fumimasa ;

Hasegawa, Tadashi ;

Yanase, Masahiro ;

Miyake, Masafumi ;

Miyao, Noriomi ;

Takahashi, Atsushi ;

Matsukawa, Masanori ;

Taguchi, Keisuke ;

Shigyo, Masanori ;

Kunishima, Yasuharu ;

Tachiki, Hitoshi ;

Tsukamoto, Taiji .

WORLD JOURNAL OF UROLOGY, 2014, 32 (05) :1281-1285

[28] Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance [J].

Oddens, Jorg ;

Brausi, Maurizio ;

Sylvester, Richard ;

Bono, Aldo ;

van de Beek, Cees ;

van Andel, George ;

Gontero, Paolo ;

Hoeltl, Wolfgang ;

Turkeri, Levent ;

Marreaud, Sandrine ;

Collette, Sandra ;

Oosterlinck, Willem .

EUROPEAN UROLOGY, 2013, 63 (03) :462-472

[29] Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG [J].